Agios Pharmaceuticals Inc
(NAS:AGIO)
$
59.04
0.02 (0.03%)
Market Cap: 3.37 Bil
Enterprise Value: 2.42 Bil
PE Ratio: 5.20
PB Ratio: 2.07
GF Score: 37/100 Agios Pharmaceuticals Inc Virtual Investor Webcast to Review Mitapivat Clinical Data Presented at EHA Annual Congress Transcript
Jun 12, 2020 / 11:30AM GMT
Release Date Price:
$47.14
(-6.97%)
Kendra Adams
Agios Pharmaceuticals, Inc. - VP of External Communications & IR
Good morning, everyone. We're going to get started here. I'm going to turn it over to Jackie. For our sell-side friends, if you have not e-mailed myself or Holly and would like to get in the lineup for the Q&A, will you just shoot us an e-mail now and we'll take questions as folks have e-mailed us and then queued up. So with that, Jackie, why don't I turn it over to you? Jackie, we can't hear you just make sure you're unmuted.
Jacqualyn A. Fouse
Agios Pharmaceuticals, Inc. - CEO & Director
Can you hear me?
Kendra Adams
Agios Pharmaceuticals, Inc. - VP of External Communications & IR
Part of it. Thank you. Yes, go ahead.
Jacqualyn A. Fouse
Agios Pharmaceuticals, Inc. - CEO & Director
Everybody. Can I get some thumbs up that you can hear me. Okay. Perfect. Thank you. Good morning, everybody. Why don't I to start off our e virtual investor webcast this morning. So thanks
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot